Zydus Lifesciences has announced another extension for its planned acquisition of Sterling Biotech Limited's (SBL) Active Pharmaceutical Ingredients (API) business. The company has now extended the closing date to June 30, 2026, marking the second extension since the original agreement was signed.

Timeline of Extensions

The acquisition timeline has seen multiple adjustments since the initial agreement. The following table outlines the progression of deadlines:

Reasons for Latest Extension

According to the company's latest regulatory filing dated December 24, 2025, Sterling Biotech is still working to complete certain conditions precedent outlined in the Business Transfer Agreement. Zydus Lifesciences stated that "SBL is still in the process of completing certain conditions precedents of the BTA and hence the Company and SBL have executed a letter to extend the closing date by June 30, 2026."

Transaction Details

The acquisition involves Sterling Biotech's API business, which represents a strategic expansion for Zydus Lifesciences in the pharmaceutical ingredients sector. The deal remains subject to the completion of various conditions precedent as specified in the original Business Transfer Agreement.

Regulatory Compliance

The company has maintained transparency throughout the process, informing stock exchanges about each development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The latest update was communicated to both BSE Limited and National Stock Exchange of India Limited.

Strategic Outlook

Despite the extended timeline, Zydus Lifesciences remains committed to completing the acquisition. The company expressed confidence that "the transaction is expected to be completed on or before June 30, 2026." The repeated extensions suggest the complexity of fulfilling all prerequisite conditions while maintaining the strategic value of the deal for both parties involved.

Zydus Lifesciences has entered into a strategic partnership with Swiss biopharmaceutical company Bioeq AG for the commercialisation of NUFYMCO, an FDA-approved interchangeable biosimilar to Lucentis (Ranibizumab) in the US market. The collaboration marks a significant expansion of Zydus's US biosimilar business portfolio, with the US biosimilar Ranibizumab market worth $210.00 million.

Partnership Details and FDA Approval

The strategic partnership involves Zydus Lifesciences Global FZE, a wholly-owned subsidiary of Zydus based in the United Arab Emirates, collaborating with Bioeq for the licensing, supply and commercialisation of NUFYMCO. The Biologics License Application (BLA) for NUFYMCO received approval from the US Food and Drug Administration (USFDA) on December 18, 2025.

Role Distribution and Responsibilities

Under the terms of the agreement, both companies will leverage their respective strengths to ensure successful market penetration. Bioeq will be responsible for the development, manufacturing, registration and supply of the finished product, while Zydus will handle the commercialisation of NUFYMCO in the US market.

This partnership follows Zydus's recent collaboration with Formycon AG for a biosimilar of Keytruda (Pembrolizumab), demonstrating the company's strategic focus on expanding its US biosimilar business through partnerships with established European biopharmaceutical companies.

Market Opportunity and Strategic Vision

The total addressable market opportunity for biosimilar Ranibizumab in the US is approximately $210.00 million as per IQVIA MAT September 2025. Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, expressed enthusiasm about the collaboration, stating that the partnership will leverage combined expertise and resources to accelerate organisational growth while ensuring maximum value to patients through expanded access to affordable ophthalmology care.

Dr. Thiemo Schreiber, Vice President Commercial at Bioeq, highlighted the regulatory approval significance and emphasised how the partnership will leverage Zydus's extensive distribution network and strong sales and marketing capabilities across the US to broaden treatment options for patients.

Company Profiles

Zydus Lifesciences Limited operates as an innovation-led life-sciences company with leadership positions across pharmaceuticals and consumer wellness, supported by an emerging MedTech franchise and a global footprint across the United States, India and other international markets. As of September 30, 2025, the group employs 29,000 people worldwide, including 1,500 scientists engaged in R&D.

Bioeq AG, established in 2014, is a Swiss biopharmaceutical joint venture between Polpharma Biologics Group and Formycon AG. The company specialises in the development, licensing, and commercialisation of biosimilars for highly regulated markets worldwide, focusing on creating cost-effective alternatives to leading biologics.